<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               <BR>                  2<BR>                    <BR>                  DOSAGE AND ADMINISTRATION<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        Femara tablets are taken orally without regard to meals (2):<BR>                        <BR>                           Recommended dose: 2.5.mg once daily (2.1)<BR><BR>                           <BR>                           Patients with cirrhosis or severe hepatic impairment: 2.5 mg every other day (2.5, 5.3)<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        2.1 Recommended Dose<BR>                     <BR>                     <BR>                        The recommended dose of Femara is one 2.5 mg tablet administered once a day, without regard to meals.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        2.<BR>                        2 Use in<BR>                         Adjuvan<BR>                        t Treatment of Early Breast Cancer<BR>                     <BR>                     <BR>                        In the adjuvant setting, the optimal duration of treatment with letrozole is unknown. The planned duration of treatment in the study was 5 years with 73% of the patients having completed adjuvant therapy. Treatment should be discontinued at relapse [<BR>                           see <BR>                           Clinical Studies <BR>                           (14.1)<BR>                           ]<BR>                           .<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        2.<BR>                        3 Use in<BR>                         Extended Adjuvant Treatment of Early Breast Cancer<BR>                     <BR>                     <BR>                        In the extended adjuvant setting, the optimal treatment duration with Femara is not known. The planned duration of treatment in the study was 5 years. In the final updated analysis, conducted at a median follow-up of 62 months, the median treatment duration was 60 months. Seventy-one percent of patients were treated for at least 3 years and 58% of patients completed least 4.5 years of extended adjuvant treatment. The treatment should be discontinued at tumor relapse [<BR>                           see <BR>                           Clinical <BR>                           Studies (<BR>                           14.<BR>                           2<BR>                           )<BR>                           ]<BR>                           . <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        2.<BR>                        4<BR>                         <BR>                        Use in <BR>                        First and Second-Line Treatment of Advanced Breast Cancer<BR>                     <BR>                     <BR>                        In patients with advanced disease, treatment with Femara should continue until tumor progression is evident. [see Clinical Studies (14.4, 14.5)]<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        2.<BR>                        5 Use in<BR>                         Hepatic Impairment<BR>                     <BR>                     <BR>                        No dosage adjustment is recommended for patients with mild to moderate hepatic impairment, although Femara blood concentrations were modestly increased in subjects with moderate hepatic impairment due to cirrhosis. The dose of Femara in patients with cirrhosis and severe hepatic dysfunction should be reduced by 50% [see<BR>                            <BR>                           Warnings and Precautions (5.<BR>                           3<BR>                           )<BR>                           ]<BR>                           . The recommended dose of Femara for such patients is 2.5 mg administered every other day. The effect of hepatic impairment on Femara exposure in noncirrhotic cancer patients with elevated bilirubin levels has not been determined.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        2.<BR>                        6 Use in<BR>                         Renal Impairment<BR>                     <BR>                     <BR>                        No dosage adjustment is required for patients with renal impairment if creatinine clearance is ≥10 mL/min. [<BR>                           s<BR>                           ee<BR>                            Clinical Pharmacology<BR>                            <BR>                           (12.3)<BR>                           ].<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>